A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

Conditions

• Pleural Metastases
• Thymic Malignancies

Eligibility Criteria

Sex

ALL

Age

18 Years - 79 Years

Healthy Volunteers

Not accepted

Interventions

• Intensity-Modulated Pleural Radiation Therapy (IMPRINT) — RADIATION
  Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.

Study Details

The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignancies. The researchers will also look at whether hemithoracic IMPRINT is effective against participants' cancer.

Key Dates

Start date

Apr 26, 2022

Status verified

May 2026

Primary completion

Apr 30, 2027

Completion

Apr 30, 2027

Study Design

Enrollment

36 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
  Radiation will be administered over approximately 6 weeks to 50.4 Gy in 28 fractions with an optional SIB to gross residual disease.

Primary Outcome Measure

assess the rate of radiation pneumonitis [ Time Frame: 2 years ]

Central Contacts

• Charles Simone, MD
  212-639-3716
  [email protected]
• Andrew Pagano, MD
  [email protected]

Locations (7)

Find similar trials in Basking Ridge, NJ